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Altered extracellular matrix (ECM) remodeling is an important part of the pathology 
of gastrointestinal (GI) disorders. In the intestine, type XVI collagen (col- 16) plays a 
role in pathogenesis by affecting ECM architecture and induce cell invasion. 
Measuring col- 16 in serum may therefore have biomarker potential in GI disorders 
such as colorectal cancer (CRC) and ulcerative colitis (UC). The aim of this study 
was to determine whether col- 16 can serve as a biomarker for altered ECM remode-
ling in patients with CRC and UC. A monoclonal antibody was raised against the 
C- terminal end of col- 16 (PRO- C16), and a competitive enzyme- linked immuno-
sorbent assay (ELISA) was developed and technically validated. Levels of PRO- C16 
were measured in serum from patients with CRC (before (n = 50) and 3 months after 
(n = 23) tumor resections), UC (n = 39) and healthy controls (n = 50). The PRO- 
C16 ELISA was specific toward the C- terminal of col- 16. PRO- C16 was signifi-
cantly elevated both in serum from patients with CRC (P = 0.0026) and UC 
(P < 0.0001) compared to controls. No difference was detected in levels of PRO- 
C16 between patients with CRC at baseline and 3 months after tumor resections 
(P > 0.999). Levels of PRO- C16 identified patients with a GI disorder with a posi-
tive predictive value of 0.9 and an odds ratio of 12 (95%CI = 4.5- 29.5, P < 0.0001). 
The newly developed assay detected significantly elevated levels of PRO- C16 in 
serum from patients with GI disorders compared to controls suggesting its potential 
as a biomarker in this setting. Future studies are needed to validate these findings.
K E Y W O R D S
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1 |  INTRODUCTION
The extracellular matrix (ECM) is a noncellular component 
responsible for maintaining tissue architecture. Altered ECM 
remodeling is a significant part of the pathology of gastroin-
testinal (GI) disorders such as colorectal cancer (CRC)1 and 
ulcerative colitis (UC).2 An imbalance between ECM forma-
tion and degradation in the colon leads to an altered composi-
tion of the ECM causing abnormal tissue function. Elevated 
deposition of ECM proteins in the tumor microenvironment 
increases the stiffness of the ECM, which influences cellular 
functions such as cell proliferation, adhesion, migration, and 
invasion.3,4 It has also become evident that inflammatory re-
sponses in the tumor microenvironment affect ECM remod-
eling.5,6 Likewise, in UC, the ECM of the intestine is highly 
affected by chronic inflammation which leads to loss of tis-
sue homeostasis and imbalanced collagen turnover.2,7-9 The 
chronic inflammation and the continuous turnover of epithe-
lial cells contribute to development of dysplasia which may 
transform into CRC.10 Biomarkers reflecting this enhanced 
ECM remodeling may therefore be important to identify pa-
tients with disruption in tissue/ECM architecture responsible 
for development and progression of CRC and UC.
In the intestine, type XVI collagen (col- 16) is suggested 
to contribute to stabilization and maintenance of basement 
membranes, a specialized layer of ECM located beneath the 
epithelial and endothelial cell layers.11 Col- 16 is a fibril- 
associated collagen with interrupted triple helices (FACITs), 
and expressed by epithelial cells and subepithelial myofibro-
blasts. These are localized subjacent to the basement mem-
brane with a pronounced deposition of col- 16 into the matrix 
of the epithelial crypts.11 Studies of skin show that col- 16 is 
localized in the dermal- epidermal junction zone near base-
ment membranes, which suggests that col- 16 has an active 
role in anchoring microfibrils to basement membranes.12,13
Col- 16 interacts with α1β1 and α2β1 integrins and induces 
the recruitment of these integrins into focal adhesion plaques, 
which promote integrin- mediated cell reactions, such as cell 
spreading and alterations in cell morphology (Figure 1).14,15 
The binding of col- 16 to integrins stimulates cell- matrix in-
teractions, which may induce an invasive phenotype in tumor 
cells. Interestingly, overexpression of col- 16 has been shown 
to induce cell invasion and a proliferative cellular phenotype 
in oral squamous cell cancer (OSCC).16,17 Col- 16 is depos-
ited at the basement membrane in normal oral epithelium 
while it seems to disappear from the basement membrane in 
tissues from OSCC patients.17 The loss of col- 16 from the 
basement membrane zone in the development of OSCC may 
induce ECM remodeling and a disruption of the basement 
membrane that promotes tumor cell infiltration and a pro-
gression of disease. In glioblastomas, col- 16 is involved in 
tumor cell adhesion and invasion as well as tumor- specific re-
modeling of the ECM.18,19 Increased expression of col- 16 has 
also been detected in intestinal subepithelial myofibroblasts 
isolated from inflamed Crohn’s disease tissue biopsies.11
Despite the observation of enhanced expression of col- 
16 concurrent to increasing inflammation in the intestine, the 
expression levels of col- 16 in UC and CRC patients remain 
unclear.
We hypothesized that col- 16 fragments may be released 
into the circulation as a part of GI pathogenesis and may 
therefore have potential as a biomarker in CRC and UC 
reflecting enhanced ECM remodeling associated with in-
flammation. Therefore, we developed a competitive enzyme- 
linked immunosorbent assay (ELISA) targeting a sequence 
identical to the C- terminal of col- 16, followed by evaluation 
of its levels in serum from patients with CRC and UC.
2 |  MATERIALS AND METHODS
2.1 | Reagents
All reagents used for the experiments were standard chemi-
cals from Merck (Whitehouse station, NJ, USA) and Sigma- 
Aldrich (St. Louis, MO, USA). The synthetic peptides used 
F I G U R E  1  Type XVI collagen in the extracellular matrix. Type XVI collagen (col- 16) is a physiological binding partner of integrins α1/
α2β1 where it induces integrin- mediated cell reactions such as cell spreading. Col- 16 binds to macromolecules of the extracellular matrix (ECM) as 
fibrillin- 1 positive microfibrils. In this study, we target the C- terminal of col- 16 with a specific antibody
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for antibody production and assay development were pur-
chased from the Chinese Peptide Company (Beijing, China) 
(Table 1).
2.2 | Selection and overview of peptides
We chose to target the C- terminal of the α1 chain of col- 
16 and name this PRO- C16. The amino acid sequence 
1595′- PMKTMKGPFG- ′1604 located at the C- terminal 
was used to generate an antibody specific for the C- terminal 
of col- 16. It was additionally used to design the selection 
peptide (PMKTMKGPFG) (Table 1). The sequence was 
blasted for homology to other human proteins and species 
using the NPS@: network protein sequence analysis with 
the Uniprot/Swiss- Prot database.20 The amino acid sequence 
is unique to human col- 16. A biotinylated peptide (Biotin- 
K- PMKTMKGPFG) was used to coat the streptavidin- 
coated plates applied in the ELISA. An elongated peptide 
(PMKTMKGPFGG), a nonsense peptide (VPKDLPPDTT), 
and a nonsense biotinylated peptide (Biotin- VPKDLPPDTT) 
were included to test the specificity of the antibody.
2.3 | Monoclonal antibody production and 
clone characterization
Generation of monoclonal antibodies was carried out as pre-
viously described.21 Briefly, four- to six- week- old Balb/C 
mice were immunized subcutaneously with 200 μL emul-
sified antigen and 50 μg immunogenic peptide (Keyhole 
Limpet Hemocyanin (KLH)- CGG- PMKTMKGPFG) using 
Freund’s incomplete adjuvant (Sigma- Aldrich). The mice 
were immunized with two- week intervals until stable serum 
titer levels were reached. The mouse with the highest serum 
titer was selected for fusion. The mouse rested one month 
was immunized intravenously with 50 μg immunogenic pep-
tide in 100 μL 0.9% sodium chloride (NaCl) solution. After 
3 days, splenocytes were isolated for cell fusion. In brief, 
splenocytes were fused with SP2/0 myeloma cells to produce 
hybridoma cells and then cloned in culture dishes using the 
semi- medium method.22 The clones were plated into 96- well 
microtiter plates, and limited dilution was used to secure 
monoclonal growth. The supernatants were screened for reac-
tivity against the selection peptide (PMKTMKGPFG) and na-
tive material (serum) in an indirect competitive ELISA using 
streptavidin- coated plates (Roche, Hvidovre, Denmark, cat. 
11940279). The clones with the best reactivity were purified 
using protein- G- columns according to the manufacturer’s 
instructions (GE healthcare Life Sciences, Little Chalfont, 
Buckinghamshire, UK). Two monoclones were tested for their 
reactivity toward the selection peptide (PMKTMKGPFG) 
and not the elongated (PMKTMKGPFGG) or nonsense pep-
tide (VPKDLPPDTT). One monoclone was chosen for assay 
development. Optimal incubation buffer, time, temperature, 
and optimal ratio between the biotinylated peptide and anti-
body were determined.
2.4 | PRO- C16 ELISA protocol
The competitive ELISA procedure was as follows: a 96- well 
streptavidin- coated microtiter plate was coated with 100 μL 
of biotinylated peptide (Biotin- K- PMKTMKGPFG) dissolved 
in assay buffer (50 mmol/L phosphate- buffered saline with 
bovine serum albumin (1% w/v), Tween- 20 (0.1% w/v), and 
bronidox (0.36% v/v) (PBS- BTB), 4 g/L NaCl, pH 7.4) (final 
concentration of 3.1 ng/mL). The plate was incubated for 
30 minutes at 20°C with shaking (300 rpm) and then washed 
five times in washing buffer (20 mmol/L TRIS, 50 mmol/L 
NaCl, pH 7.2). A volume of 20 μL of sample/control/selec-
tion peptide (PMKTMKGPFG) was added followed by im-
mediately addition of 100 μL of monoclonal antibody diluted 
in assay buffer (final concentration of 62.5 ng/mL). The plate 
was incubated for 1 hour at 20°C with shaking followed by five 
washes in washing buffer. Then, 100 μL of goat anti- mouse 
horseradish peroxidase (HRP)- conjugated IgG antibody 
(Thermo Scientific, Waltham, MA, USA; cat. #31437) diluted 
in assay buffer (final concentration of 130 ng/mL) was added 
to each well. The plate was incubated for 1 hour at 20°C with 
shaking and subsequently washed five times in washing buffer. 
Next, 100 μL Tetramethylbenzidine (TMB, Kem- En- Tec 
Diagnostics, Taastrup, Denmark) was added and incubated for 
15 minutes at 20°C with shaking in the dark. To stop the reac-
tion of TMB, 100 μL of 1% sulfuric acid (H2SO4) was added 
and the plate was analyzed in a VersaMax ELISA microplate 
reader at 450 nm with 650 nm as reference. A standard curve 
was plotted using a 4- parametric mathematical fit model, and 
data were analyzed using the Softmax Pro v. 6.3 software.
2.5 | Technical evaluation
Antibody specificity was calculated as percentage of signal inhi-
bition of twofold diluted selection peptide (PMKTMKGPFG), 
elongated peptide (PMKTMKGPFGG), or nonsense peptide 
(VPKDLPPDTT). Lower limit of measurement range (LLMR) 




Immunogenic peptide KLH- CGG- PMKTMKGPFG
Biotinylated peptide Biotin- K- PMKTMKGPFG
Elongated peptide PMKTMKGPFGG
Nonsense peptide VPKDLPPDTT
Nonsense biotinylated peptide Biotin- VPKDLPPDTT
KLH, Keyhole Limpet Hemocyanin.
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and upper limit of measurement range (ULMR) were calculated 
based on the standard curve from 10 independent runs. A two-
fold dilution of healthy serum samples from humans (n = 3) 
was used to determine linearity and calculated as percentage re-
covery of the undiluted sample. Ten independent runs of seven 
samples that covered the detection range (LLMR- ULMR) of the 
PRO- C16 were used to calculate the intra- and- interassay vari-
ation. The seven samples included three human serum samples 
and four samples with selection peptide spiked in assay buffer. 
The intra- assay variation was determined as the mean coeffi-
cient of variance (CV%) within plates, and the interassay varia-
tion was calculated as the mean CV% between plates. Accuracy 
was determined from three human serum samples spiked with 
twofold dilutions of the selection peptide and calculated as 
percentage recovery of the expected concentration (serum and 
peptide combined). The analyte stability was determined for 
three healthy serum samples subjected to up to four freeze and 
thaw cycles. The freeze- thaw recovery was calculated with the 
first cycle as reference. Analyte stability was furthermore de-
termined by incubation of three human serum samples at either 
4°C or 20°C for 24 or 48 hours. Recovery was calculated with 
samples stored at −20°C as reference. Interference was deter-
mined by adding low/high content of biotin (1.5/4.5 ng/mL), 
lipid (0.75/2.5 mg/mL) or hemoglobin (1.25/2.5 mg/mL) to 
serum samples of known concentrations and calculated as the 
percentage recovery of analyte in nonspiked serum.
2.6 | Patient serum samples
Serum samples from CRC patients were collected by medical 
staff at Bispebjerg Hospital, Copenhagen, Denmark subsequent 
to informed consent and approval by the Ethical Committee 
of the Capital Region of Denmark (Copenhagen, Denmark; 
approval no. H- 1- 2014- 048) in compliance with the Helsinki 
Declaration. Both men and females were included in the study. 
Patients were excluded if: (a) they were under 18 years of age, 
(b) they were pregnant, (c) they were diagnosis with a psychotic 
disorder or dementia, (d) they had received prior chemotherapy 
or other cancer therapy. Serum samples were collected before 
(baseline) and 3 months after tumor resections (month 3) from 
50 and 23 patients, respectively. The main reason for the re-
duced patient number 3 months after tumor resection was that 
patients did not show up to this voluntary control visit. Tumor 
staging was evaluated according to the Union for International 
Cancer Control classification system.
Serum samples from UC patients (n = 39) were obtained 
from Odense University Hospital (Odense, Denmark) after 
informed consent. The study was approved by the local eth-
ics committee of Southern Denmark (S- 20070072) and the 
Danish Data Protection Agency (2007- 41- 0675). Patients 
were included if: (a) they had known UC, (b) they had at least 
one previous flare of clinical and endoscopic active disease, 
(c) age 18 and above. Exclusion criteria were as follows: (a) 
changes in azathioprine dosage within the past 3 months, (b) 
patients with toxic megacolon, (c) peritonitis or severe co-
lonic bleeding, (d) known immunodeficiency, (e) ongoing 
infectious disease, (f) ongoing treatment with nonsteroidal 
anti- inflammatory drugs or cholestyramine, (g) pregnant or 
lactating women.9 Levels of PRO- C16 in the CRC and UC pa-
tients were compared to levels in commercially available con-
trol sera from healthy donors (n = 50) (Valley BioMedical, 
Winchester, VA, USA) who according to manufacturer’s in-
formation all filed informed consent. Information associated 
with the included patients is shown in Table 2.




Colorectal cancer Baseline 
n = 50




Median age years (range) 51 (19- 85) 71 (32- 90) 70 (32- 83) 32 (22- 62)
Gender (% females) 8% 48% 43.5% 58.3%
Tumor stage
I — 7 5 —
II — 27 13 —
III — 9 3 —
IV — 4 2 —
N/A — 3 — —
Treatment
No adjuvant treatment — 24 14 —
Adjuvant treatment 
(chemotherapy)
— 17 8 —
N/A — 9 1 —
St. Mark score, median 
(range)
— — — 3 (0- 6)
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2.7 | Statistical analyses
Kruskal- Wallis test was used to compare serum levels of 
PRO- C16 in controls, CRC patients at baseline and UC pa-
tients. Wilcoxon test was used to compare CRC patients at 
baseline and 3 months after tumor resection. The odds ratio, 
sensitivity, specificity, and negative and positive predictive 
values were generated from a specific cutoff value, obtained 
from the area under the receiver operating characteristics 
(AUROC) curve, and analyzed using Fisher’s exact probabil-
ity test and chi- square test. A P- value of P < 0.05 was con-
sidered statistical significant. GraphPad Prism, version 7.01 
(GraphPad Software, San Diego, CA, USA) was used for all 
statistical analyses.
3 |  RESULTS
3.1 | Specificity of the PRO- C16 assay
The specificity of the newly developed PRO- C16 ELISA was 
evaluated by investigating the inhibitory effect of different 
peptides. The selection peptide (PMKTMKGPFG) inhib-
ited the signal to 6% at the highest concentration while an 
elongated peptide (PMKTMKGPFGG) and a nonsense pep-
tide (VPKDLPPDTT) inhibited the signal to 81% and 97%, 
respectively (Figure 2). No reactivity was observed toward 
a nonsense biotinylated peptide (Biotin- VPKDLPPDTT). 
Altogether, this indicates that the antibody is specific to a 
peptide sequence identical to the C- terminal of col- 16.
3.2 | Technical evaluation of the 
PRO- C16 assay
Several tests were included to evaluate the overall technical 
performance of the PRO- C16 assay (Table 3). The meas-
urement range was determined by calculating the LLMR 
and ULMR, which provided a range of 0.87- 95.50 ng/mL. 
Intra- and interassay variation was 10% and 15%, respec-
tively. Native reactivity was observed in human serum. 
The dilution recovery in serum was 95% observed from 
undiluted to a 1:4 dilution. Spiking of standard peptide in 
human serum resulted in a mean recovery of 99%, indicat-
ing accuracy and that sample matrix do not affect assay 
response. The stability of the analyte was acceptable after 
four freeze- thaw cycles with a 103% recovery. The analyte 
was also recovered after prolonged storage of human serum 
at 4°C for 24 or 48 hours, resulting in a 106% and 95% 
recovery, respectively. Storage at 20°C for 24 or 48 hours 
resulted in a 91% and 85% recovery, respectively. No in-
terference was detected from either low or high levels of 
biotin, lipids, or hemoglobin.
3.3 | Serum PRO- C16 levels are higher 
both in patients with colorectal cancer and 
ulcerative colitis compared to healthy controls
To determine the biomarker potential of col- 16, we meas-
ured PRO- C16 levels both in serum from patients with CRC 
and UC compared to healthy controls. PRO- C16 levels 
were significantly elevated in patients with CRC (1.07 ng/
F I G U R E  2  Specificity of the PRO- C16 assay. The percentage of 
inhibition at given concentrations in the competitive PRO- C16 ELISA 
tested with the selection peptide (PMKTMKGPFG), an elongated 
peptide (PMKTMKGPFGG), a nonsense peptide (VPKDLPPDTT), 
and a nonsense biotinylated peptide (Biotin- K- PMKTMKGPFG). 
%B/B0: B equals the OD at × nmol/L peptide and B0 equals the OD at 
0 nmol/L peptide
T A B L E  3  Technical validation of the PRO- C16 assay
Technical validation step Results
Detection range (LLMR- ULMR) 0.87- 95.50 ng/mL
Intra- assay variation 10%
Inter- assay variation 15%
Dilution recovery in serum 95%
Spiking recovery in serum 99%
Freeze- thaw recovery in serum 103%
Analyte stability in serum 24 h, 4°C/20°C 106%/91%
Analyte stability in serum 48 h, 4°C/20°C 95%/85%
Interference
Recovery in Biotin low/high 94%/113%
Recovery in Lipid low/high 137%/118%
Recovery in Hemoglobin low/high 97%/100%
LLMR, lower limit of measurement range; ULMR, upper limit of measurement 
range. Percentages are reported as mean.
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mL, 95%CI = 0.87- 1.34, P = 0.0026) and UC (1.31 ng/mL, 
95%CI = 1.03- 1.65, P < 0.0001) compared to healthy con-
trols (0.87 ng/mL, 95%CI = 0.87- 0.91) (Figure 3A). The 
percentage of CRC and UC cases of the total tested popula-
tion increased stepwise with increasing quartile (Figure 3B). 
Of the population with PRO- C16 levels in the upper quartile 
(Q4), 97% (34/35) were CRC or UC patients while 3% (1/35) 
were healthy controls. PRO- C16 was able to identify patients 
with a GI disorder (CRC + UC) with a positive predictive 
value of 0.9 and an odds ratio of 12 (95%CI = 4.5- 29.5, 
P < 0.0001). The negative predictive value was 0.6. The 
diagnostic power (AUROC) of PRO- C16 for a patient suf-
fering from a GI disorder compared to healthy controls was 
0.73 (95%CI = 0.64- 0.81, P < 0.0001). The ROC curve, as 
well as the sensitivity and specificity are shown in Figure 4. 
Thus, measuring PRO- C16 in serum has biomarker potential 
in GI disorders.
When PRO- C16 levels were compared (paired) between 
the CRC patients before tumor resections (baseline) and 
3 months after tumor resections (month 3), no difference was 
observed (P > 0.9999) (Figure 3C). In addition, when divid-
ing the patients into two groups: those receiving adjuvant 
treatment and those not receiving treatment, still no differ-
ence could be detected in PRO- C16 levels at the two time-
points, suggesting that the PRO- C16 levels are not affected 
by this treatment (data not shown). This indicates that col- 16 
does not originate from the primary tumor.
As the tumor stage is an important clinical tool in CRC, 
the PRO- C16 levels were divided according to tumor stage 
(Figure 5). No significant difference was detected between 
the tumor stages. However, a trend was observed for elevated 
levels of PRO- C16 in stages II and III.
4 |  DISCUSSION
In the present study, we developed and validated a robust 
competitive ELISA that enables noninvasive measurement of 
PRO- C16. Using our PRO- C16 assay, we observed signifi-
cantly elevated levels of PRO- C16 both in serum from patients 
with CRC and UC compared to healthy controls. Of note, no 
difference in PRO- C16 levels was observed after tumor resec-
tions compared to baseline. To our knowledge, this is the first 
study to show that PRO- C16 can be measured in serum and 
that PRO- C16 has biomarker potential for GI disorders.
The observation that PRO- C16 was elevated in both UC 
and CRC suggests a link between col- 16 and diseases of the 
F I G U R E  3  Serum PRO- C16 levels are higher both in patients with colorectal cancer (CRC) and ulcerative colitis (UC) compared to healthy 
controls. A, PRO- C16 levels in serum from controls (n = 50), CRC (n = 50), and UC patients (n = 39). Levels below lower limit of measurement 
range (LLMR) are adjusted to LLMR. Error bars represent the median ± 95%CI of the patients measured in duplicates. Groups were compared 
using Kruskal- Wallis test. B, Levels of PRO- C16 in serum from CRC patients, UC patients, and controls divided by quartiles (Q). Patients with 
levels below the median (Q1/Q2), range 0.87- 0.93 ng/mL. Patients with levels above the median and under the upper quartile (Q3), range 0.93- 
1.35 ng/mL. Patients with levels in the upper quartile (Q4), range 1.38- 2.27 ng/mL. The number of controls, CRC, and UC patients in each group is 
illustrated. C, PRO- C16 levels were compared in serum from CRC patients at baseline and 3 months after tumor resections (month 3). Statistically 
significant difference was determined using the paired Wilcoxon test
F I G U R E  4  Receiver operating characteristics (ROC) analysis. 
ROC curve analysis was used to evaluate the ability of PRO- C16 to 
discriminate between CRC and UC patients and healthy controls
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intestine, which has been described previously.11 In support 
of this, the similar PRO- C16 levels in serum from CRC pa-
tients before and 3 months after tumor resections propose 
that col- 16 does not only originate from the primary tumor 
but also other places in the colon where it may rather reflect 
an unhealthy GI phenotype; PRO- C16 levels may be indica-
tive of pathological events in the colon.
Increased levels of col- 16 have been demonstrated in in-
flamed intestinal tissue.11 It could be speculated that the ele-
vated expression of col- 16 has a role during progression and/
or maintenance of inflammation in the inflamed tissue.11 Data 
implicates that the increased col- 16 in inflamed colon tissue 
induces a prolonged adhesion of intestinal subepithelial myo-
fibroblasts to the underlying matrix.11 Increased col- 16 would 
therefore help to promote a pathological maintenance of the 
myofibroblasts at the inflammation site causing continuous fi-
brotic responses with excessive accumulation of ECM compo-
nents.23 Thus, col- 16 could be implicated in the pathogenesis 
of fibrostenotic phenotypes in inflammatory bowel diseases.
Upregulation of col- 16 has previously been identified as 
a potential mediator of localized mechanical stiffness in high 
mammographic density tissue.24 Altered ECM remodeling 
is an important part of cancer development, and excessive 
collagen turnover products are released during CRC progres-
sion.1,25 Consistent with this, we observed increased levels of 
PRO- C16 in serum from patients with CRC (Figure 3A). In 
the tumor microenvironment, increased col- 16 may induce 
prolonged adhesion of fibroblasts, which leads to deposition 
of collagen and tissue stiffness associated with CRC progres-
sion.26 Col- 16 is upregulated by transforming growth fac-
tor- β (TGF- β), and high levels of TGF- β have been shown 
to be associated with metastasis and poor outcome in CRC 
patients.27,28 As the tumor stroma plays a crucial role in 
tumor progression, there are increasing efforts in developing 
anti- fibrotic drugs targeting the stroma in cancer patients.29 
It could be speculated that anti- fibrotic treatments also are 
going to be tested in CRC patients and biomarkers reflecting 
changes in the ECM would therefore be essential.
A trend was observed for elevated levels of PRO- C16 in 
patients with stages II and III CRC compared to stage I sug-
gesting that col- 16 may have a role in cell invasion. Col- 16 
has shown to promote formation of focal adhesion contacts 
and cell spreading in colon tissue.11 In addition, col- 16 has 
previously shown to induce cell invasion in OSCC and glio-
blastomas.16,18,19 Col- 16 induces matrix metalloproteinase 9 
(MMP9) expression, which modulates the tumor microenvi-
ronment and has been associated with the acquisition of an 
invasive phenotype in many tumors.16 Therefore, we would 
also expect higher PRO- C16 levels in stage IV. The low level 
of PRO- C16 at stage IV is calculated from four patients. Thus, 
further studies are needed to validate these observations.
The monoclonal antibody was shown to be specific toward 
an amino acid sequence identical to the C- terminal of col- 16. 
The C- terminal contains the NC1 domain, which of other col-
lagens has shown to exhibit signaling properties and have bio-
marker potential.30,31 Therefore, we found it relevant to raise this 
novel monoclonal antibody for use in an ELISA instead of using 
commercially available polyclonal antibodies. One limitation is 
that the assays’ antibody specificity only could be investigated 
for the target peptide sequence used to generate the monoclonal 
antibody, or other recombinant derivatives of col- 16 with simi-
lar limitations, that is, a non- native col- 16 fragment.
Technical evaluation of PRO- C16 included the estab-
lishment of detection range, inter- and intra- assay variation, 
dilution recovery, analyte stability, and interference, which 
all were within prespecified acceptable limits (Table 3). 
Moreover, when spiking the analyte into serum and calculat-
ing the percentage recovery, this was also within acceptable 
limits indicating that the assay has accuracy toward the ana-
lyte of interest in serum (Table 3). In summary, the PRO- C16 
assay was technically robust, specific, and accurate.
The present study is limited by the available clinical infor-
mation and the fact that age and gender could be confounding 
factors. Hence, it will be desirable to study the level of PRO- 
C16 in age- and gender- matched samples and with more clin-
ical information available.
In conclusion, PRO- C16 can be quantified in serum by 
the technically robust and specific PRO- C16 assay. Our study 
demonstrates significantly elevated PRO- C16 levels in CRC and 
UC patients compared to healthy controls, suggesting a patholog-
ical role of col- 16 in the colon. Future studies will determine the 
exact role and biomarker potential of PRO- C16 in GI disorders.
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